GLP-1 Weight-Loss Drug Market to Expand Globally Amid Growing Demand and Challenges
The GLP-1 weight-loss drug market in China, India, and Brazil is projected to grow from $6.6 billion to $22 billion by 2035, driven by rising diabetes and obesity rates, improved affordability, and wider access, according to JP Morgan. While uptake remains low in some regions due to cost and cultural factors, companies like L'Oreal are adapting skincare products to address side effects from rapid weight loss. Meanwhile, in the US, increased use of GLP-1 drugs has led some users to turn to dietary supplements, raising concerns among doctors and regulators about their regulation and safety.
First-hand measurement across 4 sources
We measured how 4 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (64/100). Lens Score 53/100.
Outlets measured: economictimes, businessstandard, businessstandard, theprint. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (54–70/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
theprint broke this story on 22 Oct, 02:53 pm. Other outlets followed.